• LAST PRICE
    58.9850
  • TODAY'S CHANGE (%)
    Trending Down-0.8650 (-1.4453%)
  • Bid / Lots
    58.8800/ 4
  • Ask / Lots
    59.1000/ 4
  • Open / Previous Close
    59.8600 / 59.8500
  • Day Range
    Low 58.5100
    High 60.2500
  • 52 Week Range
    Low 42.2100
    High 76.9800
  • Volume
    201,042
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 59.85
TimeVolumeIMCR
09:32 ET434060.23
09:34 ET14760
09:48 ET330060.06
09:50 ET122559.86
09:52 ET320060.065
09:54 ET10060.045
09:56 ET50060
09:57 ET150060.025
09:59 ET40060.025
10:01 ET62459.82
10:06 ET20059.77
10:15 ET10059.755
10:19 ET172059.56
10:21 ET65059.66
10:24 ET35459.835
10:28 ET30059.94
10:35 ET10059.775
10:37 ET10059.75
10:42 ET10059.78
10:46 ET30059.955
10:48 ET465259.87
10:51 ET401859.81
10:53 ET42859.815
10:55 ET20059.825
10:57 ET10059.805
11:00 ET50059.79
11:02 ET20059.69
11:04 ET40059.61
11:06 ET10059.375
11:08 ET30059.39
11:09 ET10059.325
11:11 ET86059.35
11:13 ET15359.285
11:15 ET20059.21
11:18 ET10059.225
11:20 ET130059.38
11:22 ET40059.29
11:24 ET10059.29
11:26 ET74059.32
11:27 ET30059.32
11:29 ET48859.325
11:31 ET39959.33
11:33 ET828359.705
11:36 ET90059.735
11:38 ET202559.69
11:40 ET40059.74
11:42 ET50059.85
11:44 ET66559.8
11:45 ET55059.8
11:47 ET52159.755
11:49 ET30059.695
11:51 ET10059.665
11:56 ET20059.52
12:00 ET10059.46
12:02 ET30059.45
12:03 ET30059.37
12:05 ET44359.38
12:07 ET30059.25
12:09 ET10059.07
12:12 ET550759.36
12:14 ET30059.43
12:16 ET27659.46
12:18 ET73159.65
12:20 ET20059.53
12:21 ET10059.505
12:23 ET26459.335
12:25 ET64059.35
12:27 ET10059.355
12:30 ET10059.35
12:32 ET10059.33
12:34 ET10059.28
12:36 ET93559.42
12:38 ET20059.425
12:39 ET11159.36
12:41 ET57859.37
12:43 ET90059.385
12:45 ET60059.415
12:48 ET11359.3
12:52 ET42159.37
12:54 ET110059.335
12:56 ET81259.3
12:57 ET3028859.22
12:59 ET118459.23
01:01 ET22659.23
01:06 ET20059.095
01:08 ET92158.97
01:10 ET10058.97
01:12 ET30058.95
01:14 ET220458.975
01:17 ET25059
01:19 ET10058.945
01:24 ET20058.84
01:28 ET20058.93
01:30 ET26058.885
01:32 ET10058.84
01:33 ET10058.785
01:35 ET40058.75
01:37 ET167258.83
01:39 ET10058.8442
01:44 ET10058.695
01:48 ET20058.65
01:53 ET205058.53
02:00 ET410058.81
02:02 ET50858.83
02:04 ET33158.83
02:06 ET151058.76
02:08 ET110458.88
02:09 ET20058.81
02:11 ET80058.745
02:13 ET2226259.0575
02:15 ET132658.78
02:18 ET10058.77
02:22 ET82258.72
02:24 ET70058.75
02:26 ET20058.7
02:27 ET10458.69
02:29 ET1436458.81
02:31 ET212559
02:33 ET108358.985
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMCR
Immunocore Holdings PLC
3.0B
-52.2x
---
United StatesCORT
Corcept Therapeutics Inc
2.8B
25.0x
+9.80%
United StatesLGND
Ligand Pharmaceuticals Inc
1.5B
16.5x
-12.71%
United StatesINVA
Innoviva Inc
955.9M
6.9x
-9.89%
United StatesEOLS
Evolus Inc
822.1M
-12.1x
---
United StatesAVDL
Avadel Pharmaceuticals PLC
1.5B
-8.7x
---
As of 2024-05-10

Company Information

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Contact Information

Headquarters
90 Park Drive, Milton Park, AbingdonABINGDON, United Kingdom OX14 4RY
Phone
123-543-8600
Fax
---

Executives

Independent Chairman of the Board
John Bell
Chief Executive Officer, Director
Bahija Jallal
Chief Financial Officer, Head of Strategy
Brian Di Donato
Chief Human Resource Officer
Tina St Leger
Head of Research and Development
David Berman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.0B
Revenue (TTM)
$249.4M
Shares Outstanding
50.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.13
Book Value
$7.42
P/E Ratio
-52.2x
Price/Sales (TTM)
12.0
Price/Cash Flow (TTM)
---
Operating Margin
-23.91%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.